Cargando…
404. The occurrence of stroke in COVID-19
BACKGROUND: Patient with COVID-19 may exhibit a wide array of neurologic manifestations, including stroke; in some cases, stroke is the presenting or predominant manifestation. The frequency of stroke in COVID-19 has varied greatly in previous reports, probably reflecting the intensity with which ne...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778080/ http://dx.doi.org/10.1093/ofid/ofaa439.599 |
_version_ | 1783631053947142144 |
---|---|
author | Wanahita, Anna Musher, Daniel M |
author_facet | Wanahita, Anna Musher, Daniel M |
author_sort | Wanahita, Anna |
collection | PubMed |
description | BACKGROUND: Patient with COVID-19 may exhibit a wide array of neurologic manifestations, including stroke; in some cases, stroke is the presenting or predominant manifestation. The frequency of stroke in COVID-19 has varied greatly in previous reports, probably reflecting the intensity with which neurologic abnormalities have been sought. The great majority of stroke have been thought to be ischemic. METHODS: Review of data, case reports, and case series RESULTS: See table 1 for a summary of reported data on neurologic manifestations of COVID-19. When MRI has been done, the great majority of strokes have been shown to be ischemic. COVID-19 causes a generalized hypercoagulable state, and arterial thromboses have been recognized in other organs, as well, involving pulmonary, mesenteric and coronary arteries. Coronavirus infection causes an intense release of cytokines with widespread activation of the coagulation cascade. In addition, SARS-CoV-2 attaches to ACE 2 receptors on endothelial surfaces via the S (spike) protein and invades causing a localized inflammatory response, with a resulting increase in local thrombotic activity. Antiphospholipid antibodies are sometimes present. New data suggest possible role of alpha-defensin level in creation and prevention of disintegration of blood clots. To date, reports of neurologic disease are based on case series, so there is no way, at present, to calculate the frequency of neurologic complications of COVID-19. A systematic, prospective study focusing on neurologic examination supplemented by MRI in hospitalized patients would answer the question of the incidence of this complication, but logistical problems including patients’ need for ICU care and concern for contagion resulting from sending patents out of the ICU for procedures mitigate against the likelihood of such a study being done. CONCLUSION: We hypothesize that: (1) stroke occurs in COVID-19 more frequently than is recognized; (2) a hypercoagulable state with inflammation at the site of local invasion of vascular endothelial cells by SARS-CoV-2, perhaps with a role for antiphospolipid antibodies all contribute to the pathogenesis of stroke; and (3) more liberal use of anticoagulation in COVID-19 cases should be considered. DISCLOSURES: All Authors: No reported disclosures |
format | Online Article Text |
id | pubmed-7778080 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77780802021-01-07 404. The occurrence of stroke in COVID-19 Wanahita, Anna Musher, Daniel M Open Forum Infect Dis Poster Abstracts BACKGROUND: Patient with COVID-19 may exhibit a wide array of neurologic manifestations, including stroke; in some cases, stroke is the presenting or predominant manifestation. The frequency of stroke in COVID-19 has varied greatly in previous reports, probably reflecting the intensity with which neurologic abnormalities have been sought. The great majority of stroke have been thought to be ischemic. METHODS: Review of data, case reports, and case series RESULTS: See table 1 for a summary of reported data on neurologic manifestations of COVID-19. When MRI has been done, the great majority of strokes have been shown to be ischemic. COVID-19 causes a generalized hypercoagulable state, and arterial thromboses have been recognized in other organs, as well, involving pulmonary, mesenteric and coronary arteries. Coronavirus infection causes an intense release of cytokines with widespread activation of the coagulation cascade. In addition, SARS-CoV-2 attaches to ACE 2 receptors on endothelial surfaces via the S (spike) protein and invades causing a localized inflammatory response, with a resulting increase in local thrombotic activity. Antiphospholipid antibodies are sometimes present. New data suggest possible role of alpha-defensin level in creation and prevention of disintegration of blood clots. To date, reports of neurologic disease are based on case series, so there is no way, at present, to calculate the frequency of neurologic complications of COVID-19. A systematic, prospective study focusing on neurologic examination supplemented by MRI in hospitalized patients would answer the question of the incidence of this complication, but logistical problems including patients’ need for ICU care and concern for contagion resulting from sending patents out of the ICU for procedures mitigate against the likelihood of such a study being done. CONCLUSION: We hypothesize that: (1) stroke occurs in COVID-19 more frequently than is recognized; (2) a hypercoagulable state with inflammation at the site of local invasion of vascular endothelial cells by SARS-CoV-2, perhaps with a role for antiphospolipid antibodies all contribute to the pathogenesis of stroke; and (3) more liberal use of anticoagulation in COVID-19 cases should be considered. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7778080/ http://dx.doi.org/10.1093/ofid/ofaa439.599 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Poster Abstracts Wanahita, Anna Musher, Daniel M 404. The occurrence of stroke in COVID-19 |
title | 404. The occurrence of stroke in COVID-19 |
title_full | 404. The occurrence of stroke in COVID-19 |
title_fullStr | 404. The occurrence of stroke in COVID-19 |
title_full_unstemmed | 404. The occurrence of stroke in COVID-19 |
title_short | 404. The occurrence of stroke in COVID-19 |
title_sort | 404. the occurrence of stroke in covid-19 |
topic | Poster Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778080/ http://dx.doi.org/10.1093/ofid/ofaa439.599 |
work_keys_str_mv | AT wanahitaanna 404theoccurrenceofstrokeincovid19 AT musherdanielm 404theoccurrenceofstrokeincovid19 |